2023-06-012024-05-312024-05-31false08541493Medicines Plus Ltd2025-01-2047730falseiso4217:GBPxbrli:pure085414932023-06-01085414932024-05-31085414932023-06-012024-05-31085414932022-06-01085414932023-05-31085414932022-06-012023-05-3108541493bus:SmallEntities2023-06-012024-05-3108541493bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3108541493bus:FullAccounts2023-06-012024-05-3108541493bus:PrivateLimitedCompanyLtd2023-06-012024-05-3108541493core:WithinOneYear2024-05-3108541493core:AfterOneYear2024-05-3108541493core:WithinOneYear2023-05-3108541493core:AfterOneYear2023-05-3108541493core:ShareCapital2024-05-3108541493core:SharePremium2024-05-3108541493core:RevaluationReserve2024-05-3108541493core:OtherReservesSubtotal2024-05-3108541493core:RetainedEarningsAccumulatedLosses2024-05-3108541493core:ShareCapital2023-05-3108541493core:SharePremium2023-05-3108541493core:RevaluationReserve2023-05-3108541493core:OtherReservesSubtotal2023-05-3108541493core:RetainedEarningsAccumulatedLosses2023-05-3108541493core:LandBuildings2024-05-3108541493core:PlantMachinery2024-05-3108541493core:Vehicles2024-05-3108541493core:FurnitureFittings2024-05-3108541493core:OfficeEquipment2024-05-3108541493core:NetGoodwill2024-05-3108541493core:IntangibleAssetsOtherThanGoodwill2024-05-3108541493core:ListedExchangeTraded2024-05-3108541493core:UnlistedNon-exchangeTraded2024-05-3108541493core:LandBuildings2023-05-3108541493core:PlantMachinery2023-05-3108541493core:Vehicles2023-05-3108541493core:FurnitureFittings2023-05-3108541493core:OfficeEquipment2023-05-3108541493core:NetGoodwill2023-05-3108541493core:IntangibleAssetsOtherThanGoodwill2023-05-3108541493core:ListedExchangeTraded2023-05-3108541493core:UnlistedNon-exchangeTraded2023-05-3108541493core:LandBuildings2023-06-012024-05-3108541493core:PlantMachinery2023-06-012024-05-3108541493core:Vehicles2023-06-012024-05-3108541493core:FurnitureFittings2023-06-012024-05-3108541493core:OfficeEquipment2023-06-012024-05-3108541493core:NetGoodwill2023-06-012024-05-3108541493core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3108541493core:ListedExchangeTraded2023-06-012024-05-3108541493core:UnlistedNon-exchangeTraded2023-06-012024-05-3108541493core:MoreThanFiveYears2023-06-012024-05-3108541493core:Non-currentFinancialInstruments2024-05-3108541493core:Non-currentFinancialInstruments2023-05-3108541493dpl:CostSales2023-06-012024-05-3108541493dpl:DistributionCosts2023-06-012024-05-3108541493core:LandBuildings2023-06-012024-05-3108541493core:PlantMachinery2023-06-012024-05-3108541493core:Vehicles2023-06-012024-05-3108541493core:FurnitureFittings2023-06-012024-05-3108541493core:OfficeEquipment2023-06-012024-05-3108541493dpl:AdministrativeExpenses2023-06-012024-05-3108541493core:NetGoodwill2023-06-012024-05-3108541493core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3108541493dpl:GroupUndertakings2023-06-012024-05-3108541493dpl:ParticipatingInterests2023-06-012024-05-3108541493dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3108541493core:ListedExchangeTraded2023-06-012024-05-3108541493dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3108541493core:UnlistedNon-exchangeTraded2023-06-012024-05-3108541493dpl:CostSales2022-06-012023-05-3108541493dpl:DistributionCosts2022-06-012023-05-3108541493core:LandBuildings2022-06-012023-05-3108541493core:PlantMachinery2022-06-012023-05-3108541493core:Vehicles2022-06-012023-05-3108541493core:FurnitureFittings2022-06-012023-05-3108541493core:OfficeEquipment2022-06-012023-05-3108541493dpl:AdministrativeExpenses2022-06-012023-05-3108541493core:NetGoodwill2022-06-012023-05-3108541493core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3108541493dpl:GroupUndertakings2022-06-012023-05-3108541493dpl:ParticipatingInterests2022-06-012023-05-3108541493dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3108541493core:ListedExchangeTraded2022-06-012023-05-3108541493dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3108541493core:UnlistedNon-exchangeTraded2022-06-012023-05-3108541493core:NetGoodwill2024-05-3108541493core:IntangibleAssetsOtherThanGoodwill2024-05-3108541493core:LandBuildings2024-05-3108541493core:PlantMachinery2024-05-3108541493core:Vehicles2024-05-3108541493core:FurnitureFittings2024-05-3108541493core:OfficeEquipment2024-05-3108541493core:AfterOneYear2024-05-3108541493core:WithinOneYear2024-05-3108541493core:ListedExchangeTraded2024-05-3108541493core:UnlistedNon-exchangeTraded2024-05-3108541493core:ShareCapital2024-05-3108541493core:SharePremium2024-05-3108541493core:RevaluationReserve2024-05-3108541493core:OtherReservesSubtotal2024-05-3108541493core:RetainedEarningsAccumulatedLosses2024-05-3108541493core:NetGoodwill2023-05-3108541493core:IntangibleAssetsOtherThanGoodwill2023-05-3108541493core:LandBuildings2023-05-3108541493core:PlantMachinery2023-05-3108541493core:Vehicles2023-05-3108541493core:FurnitureFittings2023-05-3108541493core:OfficeEquipment2023-05-3108541493core:AfterOneYear2023-05-3108541493core:WithinOneYear2023-05-3108541493core:ListedExchangeTraded2023-05-3108541493core:UnlistedNon-exchangeTraded2023-05-3108541493core:ShareCapital2023-05-3108541493core:SharePremium2023-05-3108541493core:RevaluationReserve2023-05-3108541493core:OtherReservesSubtotal2023-05-3108541493core:RetainedEarningsAccumulatedLosses2023-05-3108541493core:NetGoodwill2022-06-0108541493core:IntangibleAssetsOtherThanGoodwill2022-06-0108541493core:LandBuildings2022-06-0108541493core:PlantMachinery2022-06-0108541493core:Vehicles2022-06-0108541493core:FurnitureFittings2022-06-0108541493core:OfficeEquipment2022-06-0108541493core:AfterOneYear2022-06-0108541493core:WithinOneYear2022-06-0108541493core:ListedExchangeTraded2022-06-0108541493core:UnlistedNon-exchangeTraded2022-06-0108541493core:ShareCapital2022-06-0108541493core:SharePremium2022-06-0108541493core:RevaluationReserve2022-06-0108541493core:OtherReservesSubtotal2022-06-0108541493core:RetainedEarningsAccumulatedLosses2022-06-0108541493core:AfterOneYear2023-06-012024-05-3108541493core:WithinOneYear2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3108541493core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3108541493core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3108541493core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3108541493core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3108541493core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3108541493bus:Director12023-06-012024-05-3108541493bus:Director22023-06-012024-05-3108541493core:FurnitureFittingsToolsEquipment2023-05-3108541493core:FurnitureFittingsToolsEquipment2023-06-012024-05-3108541493core:FurnitureFittingsToolsEquipment2024-05-31

Medicines Plus Ltd

Registered Number
08541493
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

Medicines Plus Ltd
Company Information
for the year from 1 June 2023 to 31 May 2024

Directors

Mr A K Sharma
Mrs G Sharma

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

08541493 (England and Wales)
Medicines Plus Ltd
Balance Sheet as at
31 May 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets37,6396,270
7,6396,270
Current assets
Stocks17,30239,397
Debtors4180,175258,941
Cash at bank and on hand233,941177,906
431,418476,244
Creditors amounts falling due within one year5(267,736)(292,360)
Net current assets (liabilities)163,682183,884
Total assets less current liabilities171,321190,154
Net assets171,321190,154
Capital and reserves
Called up share capital100100
Profit and loss account171,221190,054
Shareholders' funds171,321190,154
The financial statements were approved and authorised for issue by the Board of Directors on 20 January 2025, and are signed on its behalf by:
Mr A K Sharma
Director
Registered Company No. 08541493
Medicines Plus Ltd
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Fixtures and fittings20
Office Equipment20
Stocks and work in progress
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
2.Average number of employees

20242023
Average number of employees during the year89
3.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 June 2364,004-64,004
Additions1,3831,6002,983
At 31 May 2465,3871,60066,987
Depreciation and impairment
At 01 June 2357,734-57,734
Charge for year1,3472671,614
At 31 May 2459,08126759,348
Net book value
At 31 May 246,3061,3337,639
At 31 May 236,270-6,270
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables153,806217,785
Other debtors22,85137,819
Prepayments and accrued income3,5183,337
Total180,175258,941
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables142,263137,648
Taxation and social security2,33018,132
Other creditors123,143136,580
Total267,736292,360
6.Related party transactions
Other creditors includes the following; The directors' current account balance of £330 (2023: £330), this relates to the directors. Medicines 4U Ltd £108,558 (2023: £126,558), this company is related by virtue of common directorship.